Collectively, our results suggest that targeting USP11 in EGFR- and TLR-driven CRC progression may provide an opportunity to disrupt multiple oncogenic pathways simultaneously, offering a potentially effective approach for CRC treatment, as shown in Fig. 8B. Here, USP11 is linked to colorectal carcinoma.